Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data show encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, according to the company. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which Quantum believes could enhance development of MS therapies, including its investigational candidate Lucid-MS.
In March 2026, Quantum submitted an Investigational New Drug (IND) application to the FDA for a Phase 2 trial of Lucid-MS. The imaging study's progress supports this regulatory pathway by potentially providing a biomarker to measure treatment effects. "Reaching the midpoint enrollment milestone is a critical step forward," the company stated in the press release. The collaboration with Massachusetts General Hospital underscores the academic validation of the imaging approach.
Quantum BioPharma is focused on developing treatments for neurodegenerative and metabolic disorders. Its lead compound, Lucid-MS, is a patented new chemical entity that has shown ability to prevent and reverse myelin degradation in preclinical models. The company also holds a 19.84% stake in Unbuzzd Wellness Inc., the maker of UNBUZZD, and retains royalty rights on sales. The full press release is available at https://ibn.fm/4IZ0y.
The imaging study's success could address a significant gap in MS research: the lack of a direct imaging method for demyelination. Current techniques often rely on indirect measures, whereas [¹⁸F]3F4AP PET may offer real-time visualization of myelin damage. If validated, this could accelerate clinical trials not only for Lucid-MS but for other demyelinating therapies. The ability to detect gray matter lesions is particularly important, as they are linked to disability progression and are often missed by conventional MRI.
Quantum's pipeline also includes other candidates for metabolic disorders and alcohol misuse. The company continues to advance its research through partnerships and internal development. For the latest updates on QNTM, visit the company's newsroom at https://ibn.fm/QNTM.
Forward-looking statements in this announcement involve risks and uncertainties, as detailed in the company's SEC filings. Investors should not place undue reliance on these statements. Quantum BioPharma undertakes no duty to update this information unless required by law.
